{"entity":{"id":"idea-tr2-payer-combo-cwe","kind":"idea","name":"Payers cover off-label combinations only inside registry-randomised trials","aka":[],"tldr":"Insurers already pay for off-label drug combinations that have never been randomised. Paying only when the patient joins a registry-based randomised comparison, as Medicare did for devices and the Cancer Drugs Fund did for cancer drugs, would turn that spending into evidence at no new drug cost.","summary":"Coverage with evidence development has been used by Medicare for devices and by NICE for cancer drugs through the Cancer Drugs Fund. Applying it to off-label combinations would fund a large pragmatic randomised programme with no new drug costs, since the drugs would be paid for anyway, and would end reimbursement of combinations that fail.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)","url":"https://doi.org/10.1016/j.cell.2017.11.009"}],"tags":[],"related":["idea-tr2-pragmatic-sequence-randomisation"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":["b-combination-space","b-drug-pricing"],"keyPapers":["paper-palmer-cell"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A coverage-with-evidence programme for off-label combinations will randomise at least 5,000 patients per year in one large payer and produce a definitive result for at least two combinations within four years.","rationale":"The Cancer Drugs Fund's managed access showed payers can collect evidence as a condition of payment; randomisation is the missing step.","test":"Pilot with one payer and two common off-label combinations with documented equipoise; measure enrolment, cost neutrality and time to answer.","maturity":"speculative","actor":"payer","cost":"medium","horizonYears":4},"route":"/ideas/idea-tr2-payer-combo-cwe/","neighbours":{"idea":[{"id":"idea-tr2-biomarker-cwe","kind":"idea","name":"Pay for new biomarker tests only while evidence of clinical utility is being collected","route":"/ideas/idea-tr2-biomarker-cwe/"},{"id":"idea-tr2-off-label-outcome-registry","kind":"idea","name":"Record what happens when doctors use cancer drugs off-label","route":"/ideas/idea-tr2-off-label-outcome-registry/"},{"id":"idea-tr2-pragmatic-sequence-randomisation","kind":"idea","name":"Registry-embedded randomisation of treatment order in routine care","route":"/ideas/idea-tr2-pragmatic-sequence-randomisation/"}],"term":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"}],"paper":[{"id":"paper-palmer-cell","kind":"paper","name":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","route":"/key-papers/paper-palmer-cell/"}]}}